title: Bladder dysfunction after gynecologic laparoscopic surgery for benign disease.
abstract: OBJECTIVE
  To estimate the incidence of and factors leading to bladder dysfunction after laparoscopic gynecological surgery for benign disorders.
  
  
  METHODS
  Prospective observational study (Canadian Task Force Classification II-3).
  
  
  METHODS
  Tertiary referral hospital in Sydney, Australia.
  
  
  METHODS
  One hundred eight women undergoing elective laparoscopic surgery for benign gynecological disease.
  
  
  METHODS
  Prospective assessment bladder function. Data were collected with respect to preoperative baseline bladder function, demographic, intraoperative and postoperative data and bladder function and time to discharge.
  
  
  RESULTS
  Postoperative bladder dysfunction was defined as a residual of >100 mL after a void of >150 mL on more than 1 occasion or a bladder volume >600 mL with no urge to void, with 20/102 (19.6%) women having postoperative bladder dysfunction. There was no statistically significant difference in baseline bladder function, mean operative time, anatomic site of surgery, number of operative sites, type of disease, duration of catheterization, or units of morphine required during hospitalization for women with or without bladder dysfunction. Women with dysfunction had a statistically significant greater length of stay from removal of catheter to discharge (28 vs 44 hours; p =.04).
  
  
  CONCLUSIONS
  Postoperative bladder dysfunction appears idiosyncratic, with no single factor predictive of this problem. Possibilities for the demonstrated rate of dysfunction include normal bladder behavior, unmasking future bladder dysfunction, response to drugs, or neurologic issues. The implications of postoperative bladder dysfunction may have consequences for health care resource use and allocation, acute patient management, and possible long-term urinary function consequences and are worthy of further study.
authors: The Royal Hospital for Women and University of New South Wales, Sydney, Australia.
authors: Ha Ryun
authors: HR
authors: Won
authors: Peta
authors: P
authors: Maley
authors: Naven
authors: N
authors: Chetty
authors: Karen
authors: K
authors: Chan
authors: Jason
authors: J
authors: Abbott
mesh_terms: D000328:Adult; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery*; D005936:Glucans / Q000009:adverse effects / Q000627:therapeutic use; D005947:Glucose / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects; D000077607:Icodextrin; D010535:Laparoscopy / Q000009:adverse effects*; D007902:Length of Stay; D010052:Ovariectomy / Q000009:adverse effects; D011446:Prospective Studies; D058994:Salpingectomy / Q000009:adverse effects; D000267:Tissue Adhesions / Q000517:prevention & control; D014463:Ultrasonography; D001743:Urinary Bladder / Q000000981:diagnostic imaging / Q000503:physiopathology*; D016055:Urinary Retention / Q000000981:diagnostic imaging / Q000209:etiology*
chemical_list: D005936:Glucans; D000077607:Icodextrin; D005947:Glucose